Bradley C. Long

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1–98 trial

P. Neven, H. Ditzel, B. Leyland-Jones, 2015, Breast Cancer Research and Treatment.

ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer

P. Neven, R. Gelber, B. Leyland-Jones, 2015, Breast Cancer Research and Treatment.

Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs

B. Leyland-Jones, J. Sparano, S. Willis, 2015, Meta gene.

Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.

C. Sotiriou, M. Dowsett, S. Loi, 2016, JAMA oncology.

High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers

R. Gray, S. Loi, B. Leyland-Jones, 2017, JCO precision oncology.

Quantitative trait locus analysis identifies Gabra3 as a regulator of behavioral despair in mice

B. H. Miller, M. Pletcher, Laura E. Schultz, 2010, Mammalian Genome.

Exploratory Analysis of Single-Gene Predictive Biomarkers in HERA DASL Cohort Reveals That C8A mRNA Expression Is Prognostic of Outcome and Predictive of Benefit of Trastuzumab

M. Dowsett, D. Karlis, U. Dafni, 2018, JCO precision oncology.